Zhou et al. investigated STOML2 expression in CRC and its association with patient prognosis (n = 95; follow-up period = 60 months), detected the variations of canonical Wnt/β-catenin signaling pathway after STOML2 inhibition in CRC cells to enhance cell growth [43]; in comparison, our work provided a larger patient cohort (n = 215) and longer follow-up period (120 months) from our center, and discovered STOML2 and PHB interaction in CRC regulating MAPK signaling. Here, PHB1 is linked to colorectal carcinoma.